NCT03856619 - To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

TERIFLUNOMIDE HMR1726

"Pharmaceutical form: Tablet~Route of administration: Oral"

Trial Locations (14)

Investigational Site Number :007, Gūrgaon

Investigational Site Number :020, Ludhiana

Investigational Site Number :001, Chandigarh

Investigational Site Number :011, Lucknow

Investigational Site Number :024, Ahmedabad

Investigational Site Number :014, Pune

Investigational Site Number :018, Nashik

Investigational Site Number :017, Bengaluru

Investigational Site Number :005, Kochi

Investigational Site Number :022, Thiruvananthapuram

Investigational Site Number :006, Kolkata

Investigational Site Number :023, Coimbatore

Investigational Site Number :026, Gūrgaon

Investigational Site Number :025, New Delhi